Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Participants who had received three doses of BNT162b2 vaccine received either a fourth dose or a bivalent vaccine containing BA.4–BA.5 mRNA; the latter group had higher neutralization against omicron variants.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 388; H. 9; S. 854 - 857
Hauptverfasser:	Zou, Jing, Kurhade, Chaitanya, Patel, Sohil, Kitchin, Nicholas, Tompkins, Kristin, Cutler, Mark, Cooper, David, Yang, Qi, Cai, Hui, Muik, Alexander, Zhang, Ying, Lee, Dung-Yang, Şahin, Ugur, Anderson, Annaliesa S., Gruber, William C., Xie, Xuping, Swanson, Kena A., Shi, Pei-Yong
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 02.03.2023
Schlagworte:	Antibodies Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Confidence intervals Coronavirus Coronaviruses Correspondence COVID-19 - immunology COVID-19 - therapy COVID-19 - virology COVID-19 Vaccines - immunology COVID-19 Vaccines - therapeutic use Humans Infections Infectious Disease mRNA SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Vaccines Vaccines, Combined - immunology Vaccines, Combined - therapeutic use Viral Infections Viruses United States > US
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Participants who had received three doses of BNT162b2 vaccine received either a fourth dose or a bivalent vaccine containing BA.4–BA.5 mRNA; the latter group had higher neutralization against omicron variants.
Bibliographie:	SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 content type line 23 Drs. Zou and Kurhade contributed equally to this letter.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMc2214916